An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer

Micro-Abstract The management of patients with oligometastatic non–small-cell lung cancer (NSCLC) is controversial. The findings of this metaanalysis of 757 oligometastatic NSCLC patients treated with ablative treatments to all sites of disease suggest that the timing of metastatic disease (synchron...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2014-09, Vol.15 (5), p.346-355
Hauptverfasser:	Ashworth, Allison B, Senan, Suresh, Palma, David A, Riquet, Marc, Ahn, Yong Chan, Ricardi, Umberto, Congedo, Maria T, Gomez, Daniel R, Wright, Gavin M, Melloni, Giulio, Milano, Michael T, Sole, Claudio V, De Pas, Tommaso M, Carter, Dennis L, Warner, Andrew J, Rodrigues, George B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - pathology Adenocarcinoma - therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Disease-Free Survival Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - pathology Lung Neoplasms - therapy Metastectomy Neoplasm Metastasis NSCLC Oligometastases Prognosis Proportional Hazards Models Pulmonary/Respiratory Radiotherapy Risk SABR/SBRT Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract The management of patients with oligometastatic non–small-cell lung cancer (NSCLC) is controversial. The findings of this metaanalysis of 757 oligometastatic NSCLC patients treated with ablative treatments to all sites of disease suggest that the timing of metastatic disease (synchronous vs. metachronous) and intrathoracic nodal status are key determinants of long-term survival. A risk classification scheme is proposed to guide clinical decision-making.
ISSN:	1525-7304 1938-0690
DOI:	10.1016/j.cllc.2014.04.003